As of Apr 26, 2024, the Regeneron Pharmaceuticals stock's PE ratio is 23.84. This takes into account the latest EPS of $37.05 and stock price of $883.2. The PE ratio marks an increase of 13% from its last 4 quarters average of 21.2.
The PE ratio of Regeneron Pharmaceuticals has averaged 38.16 over the last ten years. The current P/E ratio of 23.84 is 38% lower than the historical average. Looking back at the last ten years, REGN's PE ratio peaked in the Mar 2015 quarter at 132.01, when the price was $451.48 and the EPS was $3.42. The lowest point was in the Dec 2021 quarter, when it reached 8.27 with a price of $631.52 and an EPS of $76.4.
Maximum annual increase: 115.36% in 2022
Maximum annual decrease: -51.21% in 2016
| Year | PE ratio | Change |
|---|---|---|
| 2023 | 23.71 | 33.13% |
| 2022 | 17.81 | 115.36% |
| 2021 | 8.27 | -44.12% |
| 2020 | 14.8 | -23.59% |
| 2019 | 19.37 | 17.47% |
| 2018 | 16.49 | -50.57% |
| 2017 | 33.36 | -22.29% |
| 2016 | 42.93 | -51.21% |
| 2015 | 87.99 | -27.94% |
| 2014 | 122.1 | 87.64% |
REGN's current PE ratio is higher than the 3 and 5-year averages, but it is lower than its 10-year average.
REGN's PE ratio stands lower than its peer stock BIIB, but it is higher than JNJ's and NVS's. Regeneron Pharmaceuticals is currently trading at a higher PE ratio (23.84) than its peers average of 17.78.
| Stock name | PE ratio | Market cap |
|---|---|---|
| JNJ Johnson & Johnson | 10.53 | $352.02B |
| NVS Novartis AG | 13.15 | $198.82B |
| AMGN Amgen Inc | 21.5 | $144.69B |
| REGN Regeneron Pharmaceuticals Inc | 23.84 | $96.94B |
| BIIB Biogen Inc | 25.95 | $30.42B |
| ALNY Alnylam Pharmaceuticals Inc | N/A | $18.05B |
REGN stock has a price to earnings ratio of 23.84 as of Apr 26, 2024.
The 3-year average price to earnings ratio for REGN stock is 14.86.
The 5-year average price to earnings ratio for REGN stock is 16.11.
Over the last ten years, the quarterly PE ratio reached its highest level at 132.01 in the Mar 2015 quarter.
REGN's price to earnings ratio is currently 38% below its 10-year historical average.
The P/E ratio is calculated by taking the latest stock price and dividing it by the EPS for the last 12 months. As of today (Apr 26, 2024), Regeneron Pharmaceuticals's share price is $883.2. The company's earnings per share for the trailing twelve months (TTM) ending Dec 2023 is $37.05. Therefore, Regeneron Pharmaceuticals's PE ratio for today is 23.84. PE RATIO(23.84) = STOCK PRICE($883.2) / TTM EPS($37.05)
All PE ratio stats are based on quarterly TTM periods, unless otherwise specified.